Maya Khalil, MD
Maya Khalil, MD, Bio:
Positions:
Assistant Professor, Medicine - Hematology & Oncology , Department of Medicine 2020-
Associate Scientist, Experimental Therapeutics , O'Neal Comprehensive Cancer Center, 2020-
Associate Scientist, O'Neal Comprehensive Cancer Center, 2020-
Chair of Data Safety Monitoring Committee- O'Neal Comprehensive Cancer Center, 2023-
Overview:
Maya Khalil, M.D., is an Assistant Professor of Medicine in the Division of Hematology & Oncology at the University of Alabama at Birmingham. She received her Hematology-Oncology training at Roswell Park Comprehensive Cancer Center, where she developed expertise in clinical trial design, drug development, and patient care. Her research was focused on the tumor immune microenvironment in non-small cell lung cancer. Her focus continues to be on understanding the immune microenvironment of thoracic malignancies (i.e small cell and non-small cell lung cancers), and developing novel agents that can manipulate it to overcome resistance to therapies. She has participated and led several clinical trials at UAB that have contributed to providing patients with novel treatment options. She also chairs the data safety monitoring committee at the O’Neal Comprehensive Cancer Center overseeing cancer related investigator initiated trials.
Research overview/interests:
-Clinical Trials
-Developmental Therapeutics Lung Cancer Immune Microenvironment
-Genomic Characterization of Lung Cancer Immunomodulation in Lung Cancer
-Increasing minority representation on clinical trials by identifying and overcoming challenges to optimizing diversity of trial participation
Education And Training:
- Doctor of Medicine, American University of Beirut, School of Medicine, 2012
- Internal Medicine Residency, University of Miami/JFK Medical Center Palm Beach Regional GME Consortium, 2017
- Hematology-Oncology Fellowship, Roswell Park Comprehensive Cancer Center/ SUNY at Buffalo-Jacobs School of Medicine and Biomedical Sciences, 2020
Financial relationships
-
Attribution:OtherType of financial relationship:Professional ServicesIneligible company:National Cancer InstituteTopic:Principal or sub investigator on clinical trialDate added:06/04/2024Date updated:06/04/2024Relationship end date:12/31/2027
-
Attribution:OtherType of financial relationship:Professional ServicesIneligible company:Johnson & JohnsonTopic:Principal or sub investigator on clinical trialDate added:06/04/2024Date updated:06/04/2024Relationship end date:12/31/2027
-
Attribution:OtherType of financial relationship:Professional ServicesIneligible company:Bristol Myers SquibbTopic:Principal or sub investigator on clinical trialDate added:06/04/2024Date updated:06/04/2024Relationship end date:12/31/2027
-
Attribution:OtherType of financial relationship:Professional ServicesIneligible company:AmgenTopic:Principal or sub investigator on clinical trialDate added:06/04/2024Date updated:06/04/2024Relationship end date:12/31/2027
-
Attribution:OtherType of financial relationship:Professional ServicesIneligible company:Other - Numab TherapeuticsTopic:Principal or sub investigator on clinical trialDate added:06/04/2024Date updated:06/04/2024Relationship end date:12/31/2027
-
Attribution:OtherType of financial relationship:Professional ServicesIneligible company:Other - Nitto BioPharmaTopic:Principal or sub investigator on clinical trialDate added:06/04/2024Date updated:06/04/2024Relationship end date:12/31/2027
-
Attribution:OtherType of financial relationship:Professional ServicesIneligible company:Other - GuardantTopic:Principal or sub investigator on clinical trialDate added:06/04/2024Date updated:06/04/2024Relationship end date:12/31/2027
-
Attribution:OtherType of financial relationship:Professional ServicesIneligible company:Other - CantargiaTopic:Principal or sub investigator on clinical trialDate added:06/04/2024Date updated:06/04/2024Relationship end date:12/31/2027
-
Attribution:OtherType of financial relationship:Professional ServicesIneligible company:Abbvie, Inc.Topic:Principal or sub investigator on clinical trialDate added:06/04/2024Date updated:06/04/2024Relationship end date:12/31/2027
-
Attribution:OtherType of financial relationship:Professional ServicesIneligible company:Astellas Pharma US, IncTopic:Principal or sub investigator on clinical trialDate added:06/04/2024Date updated:06/04/2024Relationship end date:12/31/2027